Latest news with #FAIRHealth
Yahoo
6 days ago
- Business
- Yahoo
The Ozempic boom could be bad news for restaurants as more than half of GLP-1 users report cutting back on dining out, report finds
GLP-1 users taking drugs like Ozempic and Wegovy are spending less on eating at restaurants and on take-out dinners, according to a new report from Bloomberg Intelligence. Changing eating habits add to a growing number of headwinds the hospitality industry is facing as a result of slow pandemic recovery and tariff-induced economic uncertainty. As restaurants grapple with how diners are responding to economic uncertainty, they may also have to contend with consumer pull-backs as a result of the rise of drugs like Ozempic and Wegovy. GLP-1 users are significantly cutting back on dining in and ordering takeout, according to a report published this week by Bloomberg Intelligence. A survey of 1,000 GLP-1 users in the U.S. found 54% of respondents said they dined out 'significantly less' or 'less' frequently since starting the medication. Nearly the same percentage reported ordering less take-out. Respondents instead are choosing to eat at home, with 70% of them reporting they're cooking at home 'significantly more' or 'more' frequently since taking GLP-1 drugs, and about half reported purchasing more groceries. GLP-1 drugs, with the ability to help some users lose weight quickly, have skyrocketed in popularity. About 4% of Americans are taking some form of GLP-1 drug for weight-loss or to treat type 2 diabetes, a 600% increase in usage from six years ago, according to May data from FAIR Health. The drugs increase insulin levels and decrease glucose levels, slowing how quickly food is digested and suppressing users' appetites. Suppressed hunger has led to some users cutting down portion sizes or needing to focus on eating nutrient-dense foods, which may deter them from dining in restaurants. Bloomberg Intelligence's research adds to growing evidence of GLP-1 users losing their appetite for dining out. A Morgan Stanley survey from April 2024 found nearly two-thirds of GLP-1 users said they spent less money at restaurants, while 31% said they cut back on groceries. The trends have led to some food companies making changes to products to account for GLP-1 users' changing appetites. In October 2024, Smoothie King added a line of high-protein and fiber products particularly for those on the medication. The year before, Nestle announced it would develop 'companion products' for GLP-1 users, should those consumers need to cut calories. GLP-1 drugmakers have taken note of some companies' anxiety. In February 2024, Lars Fruergaard Jørgensen, the CEO of Ozempic-maker Novo Nordisk, said he was fielding calls from 'scared' food company executives about the impact of the drug on the industry. The Bloomberg Intelligence report notes the dining out slowdown among GLP-1 users could be exacerbated by other economic pressures. The decrease in away-from-home dining was reported significantly across incomes, from those earning less than $50,000 to those with $150,000 or greater annual salaries, indicating a broader shift in dining trends. The report also posited that restaurants serving fewer healthy options like fast-food could be most impacted by changing eating habits. Indeed, it's not just evolving dining habits that the restaurant industry has had to contend with. The hospitality sector has had to navigate the impact of greater economic headwinds, including a widespread labor shortage that never quite recovered from the pandemic, as well as growing uncertainty about tariffs, which have led consumers confidence to plunge. Campbell's CEO Mick Beekhuizen said in an earnings call this week canned soup sales are soaring, likely a result of tighter food budgets and consumers deciding to cook at home instead of going out to eat. 'We started to see consumer sentiment softening in January,' he said. 'This continued throughout [the quarter] with consumers making more deliberate choices with their spending on food. A key outcome is a growing preference for home-cooked meals, leading to the highest levels of meals prepared at home since early 2020.' Hospitality industry experts have noted that Gen Z is also cutting back on their order sizes bysplitting appetizers, ordering kids' meals, and skipping out on alcohol to save money. Despite evidence that GLP-1 users are significantly cutting back on restaurant dining, some restaurateurs have shrugged off concerns about the drug's impact on business. Michael Osanloo, president and CEO of Portillo's Restaurant Group told Bloomberg TV last year GLP-1 use taking a bite out of the restaurant business could be a coastal problem, not one for the U.S. Midwest. 'It's totally overblown,' Osanloo said. 'I think it's a fun narrative to propose, but I don't see any impact on our business.' This story was originally featured on
Yahoo
27-05-2025
- Business
- Yahoo
Use of GLP-1 Drugs to Treat Overweight or Obesity Increased 587 Percent from 2019 to 2024, According to New FAIR Health Study
GLP-1 Prescriptions Increased 364 Percent for All Adults, and 588 Percent for Younger Adults Bariatric Surgeries Declined 42 Percent NEW YORK, May 27, 2025 /PRNewswire/ -- Over two percent of adult patients now take a GLP-1 drug to treat overweight or obesity, according to newly released FAIR Health data. Among all adult patients, the percentage who had an overweight or obesity diagnosis and were prescribed a GLP-1 drug increased from 0.30 percent in 2019 to 2.05 percent in 2024, a relative increase of 586.7 percent. The percentage who received an overweight or obesity diagnosis but no type 2 diabetes diagnosis increased 1,960.9 percent, from 0.03 percent to 0.67 percent. These and other findings are reported in a FAIR Health white paper released today: Obesity and GLP-1 Drugs: A Claims-Based Analysis. The percentage of all commercially insured adult patients prescribed a GLP-1 drug increased from 0.9 percent in 2019 to 4.0 percent in 2024, a relative increase of 363.7 percent, with prescriptions for young adults (aged 18-39) increasing 587.8 percent over that time, from 0.19 percent to 1.33 percent. The percentage of adult patients who had bariatric surgery decreased from 0.12 percent in 2019 to 0.07 percent in 2024, a relative decrease of 41.8 percent. Obesity is a common and serious disease. In recent years, a new class of medications for obesity has become available: glucagon-like peptide-1 (GLP-1) receptor agonists. In this report, FAIR Health delves into its repository of over 51 billion commercial healthcare claim records, the nation's largest such database, to examine trends in obesity and GLP-1 drug prescriptions among adult patients during the period 2019-2024. This study focuses on trends in diagnosis of overweight, obesity and type 2 diabetes, as well as GLP-1 drugs and other obesity treatment options (including bariatric surgery and behavioral health services). The key findings include the following: From 2019 to 2024, the percentage of adult patients with a diagnosis of overweight or obesity increased from 10.4 percent in 2019 to 15.7 percent in 2024, a relative increase of 50.7 percent. As discussed in the Results section of the white paper, many adult patients who are overweight or obese may not receive a medical diagnosis of overweight or obesity. Among all adult patients prescribed a GLP-1 drug, the percentage who had an overweight or obesity diagnosis and no type 2 diabetes diagnosis increased from 3.7 percent in 2019 to 16.5 percent in 2024, a relative increase of 344.4 percent. Diagnoses of pancreatitis increased from 0.17 percent in the year before the first GLP-1 drug prescription to 0.31 percent in the year after for patients who did not have a type 2 diabetes diagnosis. This was an increase of over 80 percent, the largest percent increase among the co-occurring diagnoses examined. From 2019 to 2024, among all adult patients with an overweight or obesity diagnosis, the percentage who were prescribed a GLP-1 drug but did not have bariatric surgery increased from 2.5 percent in 2019 to 11.2 percent in 2024, a relative increase of 339.5 percent. In 2024, over 80 percent of patients with an overweight or obesity diagnosis did not receive a GLP-1 prescription, bariatric surgery or behavioral health service. Only 11.2 percent of such patients received a GLP-1 prescription, 6.3 percent received behavioral health services and 0.28 percent had bariatric surgery. The use of behavioral health services decreased dramatically for patients prescribed GLP-1 drugs during the study period. Out of all patients with an overweight or obesity diagnosis who were prescribed a GLP-1 drug, the percentage of patients who had behavioral health services related to their condition declined from 2019 to 2024. In 2019, 47.2 percent of such patients had behavioral health services, but in 2024, only 12.4 percent of patients did, a relative decrease of 73.7 percent. For the complete white paper, click here. Follow us on X @FAIRHealth About FAIR Health FAIR Health is a national, independent nonprofit organization that qualifies as a public charity under section 501(c)(3) of the federal tax code. It is dedicated to bringing transparency to healthcare costs and health insurance information through data products, consumer resources and health systems research support. FAIR Health possesses the nation's largest collection of commercial healthcare claims data, which includes over 51 billion claim records and is growing at a rate of about 4 billion claim records a year. FAIR Health licenses its commercial data and data products—including benchmark modules, data visualizations, custom analytics and market indices—to commercial insurers and self-insurers, employers, providers, hospitals and healthcare systems, government agencies, researchers and others. Certified by the Centers for Medicare & Medicaid Services (CMS) as a national Qualified Entity, FAIR Health also receives data representing the experience of all individuals enrolled in traditional Medicare Parts A, B and D, which accounts for a separate collection of over 51 billion claim records; FAIR Health includes among the commercial claims data in its database, data on Medicare Advantage enrollees. FAIR Health can produce insightful analytic reports and data products based on combined Medicare and commercial claims data for government, providers, payors and other authorized users. FAIR Health's systems for processing and storing protected health information have earned HITRUST CSF certification and achieved AICPA SOC 2 Type 2 compliance by meeting the rigorous data security requirements of these standards. As a testament to the reliability and objectivity of FAIR Health data, the data have been incorporated in statutes and regulations around the country and designated as the official, neutral data source for a variety of state health programs, including workers' compensation and personal injury protection (PIP) programs. FAIR Health data serve as an official reference point in support of certain state balance billing laws that protect consumers against bills for surprise out-of-network and emergency services. FAIR Health also uses its database to power a free consumer website available in English and Spanish, which enables consumers to estimate and plan for their healthcare expenditures and offers a rich educational platform on health insurance. An English/Spanish mobile app offers the same educational platform in a concise format and links to the cost estimation tools. The website has been honored by the White House Summit on Smart Disclosure, the Agency for Healthcare Research and Quality (AHRQ), URAC, the eHealthcare Leadership Awards, appPicker, Employee Benefit News and Kiplinger's Personal Finance. For more information on FAIR Health, visit Contact:Rachel KentExecutive Director of Communications and MarketingFAIR Health646-396-0795rkent@ View original content to download multimedia: SOURCE FAIR Health Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27-05-2025
- Business
- Yahoo
Use of GLP-1 Drugs to Treat Overweight or Obesity Increased 587 Percent from 2019 to 2024, According to New FAIR Health Study
GLP-1 Prescriptions Increased 364 Percent for All Adults, and 588 Percent for Younger Adults Bariatric Surgeries Declined 42 Percent NEW YORK, May 27, 2025 /PRNewswire/ -- Over two percent of adult patients now take a GLP-1 drug to treat overweight or obesity, according to newly released FAIR Health data. Among all adult patients, the percentage who had an overweight or obesity diagnosis and were prescribed a GLP-1 drug increased from 0.30 percent in 2019 to 2.05 percent in 2024, a relative increase of 586.7 percent. The percentage who received an overweight or obesity diagnosis but no type 2 diabetes diagnosis increased 1,960.9 percent, from 0.03 percent to 0.67 percent. These and other findings are reported in a FAIR Health white paper released today: Obesity and GLP-1 Drugs: A Claims-Based Analysis. The percentage of all commercially insured adult patients prescribed a GLP-1 drug increased from 0.9 percent in 2019 to 4.0 percent in 2024, a relative increase of 363.7 percent, with prescriptions for young adults (aged 18-39) increasing 587.8 percent over that time, from 0.19 percent to 1.33 percent. The percentage of adult patients who had bariatric surgery decreased from 0.12 percent in 2019 to 0.07 percent in 2024, a relative decrease of 41.8 percent. Obesity is a common and serious disease. In recent years, a new class of medications for obesity has become available: glucagon-like peptide-1 (GLP-1) receptor agonists. In this report, FAIR Health delves into its repository of over 51 billion commercial healthcare claim records, the nation's largest such database, to examine trends in obesity and GLP-1 drug prescriptions among adult patients during the period 2019-2024. This study focuses on trends in diagnosis of overweight, obesity and type 2 diabetes, as well as GLP-1 drugs and other obesity treatment options (including bariatric surgery and behavioral health services). The key findings include the following: From 2019 to 2024, the percentage of adult patients with a diagnosis of overweight or obesity increased from 10.4 percent in 2019 to 15.7 percent in 2024, a relative increase of 50.7 percent. As discussed in the Results section of the white paper, many adult patients who are overweight or obese may not receive a medical diagnosis of overweight or obesity. Among all adult patients prescribed a GLP-1 drug, the percentage who had an overweight or obesity diagnosis and no type 2 diabetes diagnosis increased from 3.7 percent in 2019 to 16.5 percent in 2024, a relative increase of 344.4 percent. Diagnoses of pancreatitis increased from 0.17 percent in the year before the first GLP-1 drug prescription to 0.31 percent in the year after for patients who did not have a type 2 diabetes diagnosis. This was an increase of over 80 percent, the largest percent increase among the co-occurring diagnoses examined. From 2019 to 2024, among all adult patients with an overweight or obesity diagnosis, the percentage who were prescribed a GLP-1 drug but did not have bariatric surgery increased from 2.5 percent in 2019 to 11.2 percent in 2024, a relative increase of 339.5 percent. In 2024, over 80 percent of patients with an overweight or obesity diagnosis did not receive a GLP-1 prescription, bariatric surgery or behavioral health service. Only 11.2 percent of such patients received a GLP-1 prescription, 6.3 percent received behavioral health services and 0.28 percent had bariatric surgery. The use of behavioral health services decreased dramatically for patients prescribed GLP-1 drugs during the study period. Out of all patients with an overweight or obesity diagnosis who were prescribed a GLP-1 drug, the percentage of patients who had behavioral health services related to their condition declined from 2019 to 2024. In 2019, 47.2 percent of such patients had behavioral health services, but in 2024, only 12.4 percent of patients did, a relative decrease of 73.7 percent. For the complete white paper, click here. Follow us on X @FAIRHealth About FAIR Health FAIR Health is a national, independent nonprofit organization that qualifies as a public charity under section 501(c)(3) of the federal tax code. It is dedicated to bringing transparency to healthcare costs and health insurance information through data products, consumer resources and health systems research support. FAIR Health possesses the nation's largest collection of commercial healthcare claims data, which includes over 51 billion claim records and is growing at a rate of about 4 billion claim records a year. FAIR Health licenses its commercial data and data products—including benchmark modules, data visualizations, custom analytics and market indices—to commercial insurers and self-insurers, employers, providers, hospitals and healthcare systems, government agencies, researchers and others. Certified by the Centers for Medicare & Medicaid Services (CMS) as a national Qualified Entity, FAIR Health also receives data representing the experience of all individuals enrolled in traditional Medicare Parts A, B and D, which accounts for a separate collection of over 51 billion claim records; FAIR Health includes among the commercial claims data in its database, data on Medicare Advantage enrollees. FAIR Health can produce insightful analytic reports and data products based on combined Medicare and commercial claims data for government, providers, payors and other authorized users. FAIR Health's systems for processing and storing protected health information have earned HITRUST CSF certification and achieved AICPA SOC 2 Type 2 compliance by meeting the rigorous data security requirements of these standards. As a testament to the reliability and objectivity of FAIR Health data, the data have been incorporated in statutes and regulations around the country and designated as the official, neutral data source for a variety of state health programs, including workers' compensation and personal injury protection (PIP) programs. FAIR Health data serve as an official reference point in support of certain state balance billing laws that protect consumers against bills for surprise out-of-network and emergency services. FAIR Health also uses its database to power a free consumer website available in English and Spanish, which enables consumers to estimate and plan for their healthcare expenditures and offers a rich educational platform on health insurance. An English/Spanish mobile app offers the same educational platform in a concise format and links to the cost estimation tools. The website has been honored by the White House Summit on Smart Disclosure, the Agency for Healthcare Research and Quality (AHRQ), URAC, the eHealthcare Leadership Awards, appPicker, Employee Benefit News and Kiplinger's Personal Finance. For more information on FAIR Health, visit Contact:Rachel KentExecutive Director of Communications and MarketingFAIR Health646-396-0795rkent@ View original content to download multimedia: SOURCE FAIR Health Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Axios
27-05-2025
- Health
- Axios
Just how many Americans are taking GLP-1s now
More than 2% of Americans are taking the blockbuster class of GLP-1 drugs for overweight or obesity, up nearly 600% over six years, according to a report from FAIR Health given to Axios first. Why it matters: The data from FAIR Health's repository of over 51 billion commercial healthcare claim records shows the explosion in use of the drugs specifically for weight loss — roughly half of all users. Details: In all, roughly 4% of Americans were taking GLP-1 drugs in 2024 for either overweight, obesity or Type 2 diabetes (their original approved use). The data shows Novo Nordisk's Ozempic is still by far the most commonly taken GLP-1, followed by Eli Lilly's Mounjaro. The percentage of adults who were prescribed a GLP-1 drug but did not have bariatric surgery increased from 2.5% in 2019 to 11.2% in 2024 while the the percentage of adult patients who had bariatric surgery decreased 41.8%. Yes, but: The data still shows a dearth of treatment for patients with overweight or obesity.
Yahoo
22-04-2025
- Health
- Yahoo
Mental Health Conditions Ranked as the Number One Telehealth Diagnostic Category Nationally and in All Regions from July to December 2024
FAIR Health's Telehealth Tracker Trending Reports Reveal Trends over Last Six Months of 2024 NEW YORK, April 22, 2025 /PRNewswire/ -- Today FAIR Health released the second edition of the Monthly Telehealth Regional Tracker Trending Reports, a free set of infographics that show national and regional trends in telehealth from July to December 2024. A brief released simultaneously offers a user's guide to the Telehealth Tracker Trending Reports. The Telehealth Tracker Trending Reports are based on the Monthly Telehealth Regional Tracker, which uses FAIR Health data to track how telehealth is evolving from month to month. The Telehealth Tracker has attracted widespread interest from media outlets as well as from key healthcare stakeholders such as researchers, government officials, health plans and providers. To add another dimension to the Telehealth Tracker, and broaden its lens, FAIR Health created the Telehealth Tracker Trending Reports, which offer a window into changes over longer periods than one month. The first set of trending reports, released on October 15, 2024, covered the period January to June 2024. This second set of trending reports show national and regional trends in telehealth utilization—as measured by telehealth's percentage of medical claim lines1—and the top five telehealth diagnostic categories across each month from July to December 2024. The data represent the commercially insured population, excluding Medicare Fee-for-Service, Medicare Advantage and Medicaid. Among the key findings from the second edition of the Telehealth Tracker Trending Reports: Telehealth utilization increased from July to December 2024 nationally and in all four US census regions. Nationally, telehealth utilization rose by 6.13 percent, from 4.74 percent in July to 5.04 percent in December. From July to December 2024, mental health conditions ranked as the number one telehealth diagnostic category nationally and in all regions. However, this diagnostic category decreased as a percentage of telehealth claim lines from July to December nationally and in all but one region (the West). Nationally, mental health conditions fell 0.46 percent, from 67.01 percent in July to 66.70 percent in December. In the Midwest, the top five diagnostic categories from July to December 2024 included two categories not found at the national level: substance use disorders and sleep disorders. The category sleep disorders, which occurred at position five in the Midwest from September to November, was not found in the top five of any other region during this period. In the Northeast, the top five diagnostic categories from July to December 2024 included one category not found at the national level: substance use disorders. The Northeast and the Midwest were the only two regions to include this category in their top five lists during this period. From July to December 2024, the South was the only region to have hypertension in its top five diagnostic categories. Hypertension also appeared in the national top five. In the West, the top five diagnostic categories from July to December 2024 included three categories not found in the top five at the national level or in any other region: COVID-19, diabetes mellitus and abnormal blood-pressure reading. For the Monthly Telehealth Regional Tracker Trending Reports, click here. For the user's guide to the July to December 2024 trending reports, click here. Follow us on X @FAIRHealth About FAIR Health FAIR Health is a national, independent nonprofit organization that qualifies as a public charity under section 501(c)(3) of the federal tax code. It is dedicated to bringing transparency to healthcare costs and health insurance information through data products, consumer resources and health systems research support. FAIR Health possesses the nation's largest collection of commercial healthcare claims data, which includes over 50 billion claim records and is growing at a rate of over 3 billion claim records a year. FAIR Health licenses its commercial data and data products—including benchmark modules, data visualizations, custom analytics and market indices—to commercial insurers and self-insurers, employers, providers, hospitals and healthcare systems, government agencies, researchers and others. Certified by the Centers for Medicare & Medicaid Services (CMS) as a national Qualified Entity, FAIR Health also receives data representing the experience of all individuals enrolled in traditional Medicare Parts A, B and D, which accounts for a separate collection of over 50 billion claim records; FAIR Health includes among the commercial claims data in its database, data on Medicare Advantage enrollees. FAIR Health can produce insightful analytic reports and data products based on combined Medicare and commercial claims data for government, providers, payors and other authorized users. FAIR Health's systems for processing and storing protected health information have earned HITRUST CSF certification and achieved AICPA SOC 2 Type 2 compliance by meeting the rigorous data security requirements of these standards. As a testament to the reliability and objectivity of FAIR Health data, the data have been incorporated in statutes and regulations around the country and designated as the official, neutral data source for a variety of state health programs, including workers' compensation and personal injury protection (PIP) programs. FAIR Health data serve as an official reference point in support of certain state balance billing laws that protect consumers against bills for surprise out-of-network and emergency services. FAIR Health also uses its database to power a free consumer website available in English and Spanish, which enables consumers to estimate and plan for their healthcare expenditures and offers a rich educational platform on health insurance. An English/Spanish mobile app offers the same educational platform in a concise format and links to the cost estimation tools. The website has been honored by the White House Summit on Smart Disclosure, the Agency for Healthcare Research and Quality (AHRQ), URAC, the eHealthcare Leadership Awards, appPicker, Employee Benefit News and Kiplinger's Personal Finance. For more information on FAIR Health, visit Contact: Rachel Kent Executive Director of Communications and Marketing FAIR Health 646-396-0795 rkent@ 1 A claim line is an individual service or procedure listed on an insurance claim. View original content to download multimedia: SOURCE FAIR Health Sign in to access your portfolio
